LOGIN  |  REGISTER
Assertio

Latest Biotechnology Stock News

FILTER BY TOPIC:     Clinical Trials   FDA Updates   FDA Approvals   Patents        List of All Biotech Stocks  

BeiGene: BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

May 24
Last Trade: 152.71 -3.46 -2.22

New network meta-analysis demonstrates favorable progression-free survival for patients treated with BRUKINSA vs other BTKi's Analysis of Kaiser Permanente database shows BRUKINSA effective and generally well tolerated, including in patients switching to BRUKINSA from ibrutinib ALPINE post hoc analysis shows less frequent initiation of new antihypertensives or a new class of antihypertensives in patients treated with BRUKINSA vs....Read more


BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting

May 24
Last Trade: 27.94 0.18 0.65

BridgeBio to host investor call on Wednesday, May 29, 2024 at 5:30 pm ET, with presentations from Mathew Maurer, M.D. of Columbia University Irving Medical Center, U.S. and Ahmad Masri, M.D., M.S. of Oregon Health & Science University, U.S. PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic...Read more


Apellis Pharmaceuticals: Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

May 24
Last Trade: 40.61 0.93 2.34

Rapid reduction in disease activity seen at 12 weeks was sustained at one year 55% of patients showed zero C3c staining intensity, indicating that C3c deposits were cleared Highlighted as late-breaking oral presentation at the European Renal Association (ERA) Congress WALTHAM, Mass. and STOCKHOLM, Sweden, May 24, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced...Read more


Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

May 24
Last Trade: 9.02 0.00 0.00

BOSTON / May 24, 2024 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024. Jessica Best, Vice President of Medical Affairs at...Read more


KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024

May 24
Last Trade: 11.30 0.01 0.09

Late-breaking presentations for sebetralstat phase 3 KONFIDENT and KONFIDENT-S trials on Friday, May 31 Multiple real-world data presentations show that delay of injectable on-demand treatment for HAE attacks remains common CAMBRIDGE, Mass. & SALISBURY, England / May 24, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the acceptance of multiple abstracts and a symposium at the European Academy...Read more


Renovaro and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy

May 24
Last Trade: 1.42 0.10 7.58

LOS ANGELES and AMSTERDAM, May 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) and the Amsterdam UMC Cancer Center today announced an intended partnership and therefore signed an MoU to establish a joint company based in the Netherlands aimed at pioneering the next generation of personalized cancer immunotherapy. Both Renovaro and Amsterdam UMC emphasize the need to carry out the appropriate corporate and scientific due...Read more


Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

May 24
Last Trade: 4.12 -8.06 -66.17

Plan to complete NDA submission with the mature RAMP 201 dataset, anticipated to include 12 months of follow-up, in the second half of 2024 Plan to present the mature dataset from RAMP 201 at a medical conference in the second half of 2024 Avutometinib and defactinib combination have continued to show robust and durable response rates in ongoing RAMP 201 trial in patients with recurrent low-grade serous ovarian cancer Company to host...Read more


Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

May 24
Last Trade: 1.09 0.03 2.83

Trial-in-progress abstract highlights new cohort that could expand the company's pancreatic cancer program Pelareorep's ability to expand TILs highlights its immunotherapeutic mechanism of action and potential as a backbone immunotherapy for multiple indications SAN DIEGO and CALGARY, AB, May 24, 2024 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for...Read more


BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

May 24
Last Trade: 0.69 0.08 13.24

New analysis of biopsy samples demonstrated a significant increase in CD8+ T-cell density in tumors from all 11 patients treated   7 of 11 patients in the pilot phase experienced a partial response, with 6 confirmed; 10 of 11 patients experienced disease control   Poster Presentation on Saturday, June 1, 2024 in Chicago, Illinois  TEL AVIV, Israel, May 24, 2024 /PRNewswire/ -- BioLineRx Ltd....Read more


IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

May 24
Last Trade: 1.01 -0.03 -2.88

NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations at the International Society for Cell & Gene Therapy 2024, to be held May 28th to June 1st in Vancouver, Canada. “ISCT is a scientific gathering renowned for fostering groundbreaking ideas and innovation in cellular therapies,” said...Read more


BriaCell Therapeutics Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024

May 24
Last Trade: 1.44 0.01 0.70

83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastases Median progression free survival (PFS) of 4.1 months in ADC resistant patients - double the PFS of patients in similar studies1,2,3 Clinical benefit rate of 55% in evaluable patients includes HR+, HER2+ and TNBC disease - much higher than comparable studies1,2,3 PHILADELPHIA and VANCOUVER, British...Read more


Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress

May 24
Last Trade: 2.03 0.02 1.00

HOUSTON, May 24, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2024 European Hematology Association (EHA) Congress, taking place June 13-16, 2024 in Madrid, Spain. Jorge Cortes, M.D., Director of the...Read more


CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

May 24
Last Trade: 32.71 0.00 0.00

IRVINE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced final results from the Phase 2 CORE-001 clinical trial of its oncolytic immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of...Read more


Regeneron Pharmaceuticals: Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO

May 23
Last Trade: 985.02 4.45 0.45

Oral presentation to highlight activity of REGN7075 in combination with Libtayo from dose-escalation portion of trial in patients with microsatellite stable colorectal cancer, which has historically proven unresponsive to immunotherapy Ongoing REGN7075 Phase 1/2 trial is investigating a potentially first-in-class combination across a range of advanced solid tumors TARRYTOWN, N.Y., May 23, 2024 (GLOBE NEWSWIRE) -- Regeneron...Read more


Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 23
Last Trade: 28.00 -1.34 -4.57

Six oral and poster presentations will highlight breadth of clinical program and potential utility of epcoritamab-bysp in patients with difficult-to-treat lymphomas across multiple lines of therapy and histologies where high unmet needs exist Results from two studies evaluating tisotumab vedotin in patients with head and neck squamous cell carcinoma and recurrent or metastatic cervical cancer accepted for oral and poster presentations,...Read more


Bio-Techne To Present At The 2024 Leerink Partners Healthcare Crossroads Conference

May 23
Last Trade: 80.79 0.38 0.47

MINNEAPOLIS, May 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the 2024 Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 8:40 a.m. CDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website...Read more


Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

May 23
Last Trade: 41.41 1.91 4.84

First disclosure from Cohort D of the Phase 2 CARTITUDE-2 study investigating CARVYKTI® in patients who had suboptimal response to frontline ASCT in an oral presentation at ASCO & EHA An oral presentation at ASCO of data from the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® in patients with functional high-risk multiple myeloma New data at EHA from the Phase 3 CARTITUDE-4 study assessing CARVYKTI® in a subgroup analysis by...Read more


Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

May 23
Last Trade: 65.54 -0.83 -1.25

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today highlights data presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held in Miami, May 28 - 31, 2024. The analyses being presented provide important...Read more


Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting

May 23
Last Trade: 102.81 0.42 0.41

Updated Phase 1 dose escalation data show that BLU-222 in combination with ribociclib and fulvestrant was well-tolerated at clinically active dose levels with no dose-limiting toxicities  Early signal of clinical activity includes compelling biomarker reductions correlated with BLU-222 exposure  CAMBRIDGE, Mass., May 23, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced updated data from...Read more


Ionis Pharmaceuticals: New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)

May 23
Last Trade: 37.28 -0.72 -1.89

– Results across NEURO-TTRansform subgroups show consistent benefit in neuropathy impairment and improved quality of life, regardless of patient segmentation – CARLSBAD, Calif., May 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new subgroup analyses from Ionis and AstraZeneca's Phase 3 NEURO-TTRansform study of WAINUA™ (eplontersen) at the 2024 International Symposium on...Read more


Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

May 23
Last Trade: 59.99 15.92 36.12

MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster presentation: June 3, 2024, 1:30-4:30 p.m. CT UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative,...Read more


Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

May 23
Last Trade: 59.99 15.92 36.12

60% response rate observed among 10 evaluable patients Favorable safety profile in 26 patients enrolled as of the abstract cutoff date, with no significant overlapping toxicities observed Conference call on Tuesday, May 28 at 8:00 a.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology...Read more


SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23
Last Trade: 42.38 -0.43 -1.00

Results from pivotal Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN to be presented in an oral presentation  Additional data and analyses from Phase 3 DeFi trial of OGSIVEO® (nirogacestat) highlighting consistent safety and efficacy across subgroups of adults with desmoid tumors also being presented in oral and poster sessions  STAMFORD, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc....Read more


IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma

May 23
Last Trade: 37.71 -0.74 -1.92

~67% eye preservation rate (6 of 9 enucleation patients) with darovasertib monotherapy neoadjuvant uveal melanoma treatment Median tumor shrinkage (maximum volume change) of ~39% after 6 months Clinical data on additional enucleation patients and with further follow-up from the abstract-summary cut-off date will be presented at ASCO 2024 Darovasertib was generally well tolerated with no drug-related serious adverse events Oral...Read more


Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting

May 23
Last Trade: 10.01 -0.25 -2.44

Lifileucel TIL Cell Therapy in Combination with Pembrolizumab DemonstratesDeep, Durable Responses in Frontline Advanced Melanoma Patients in IOV-COM-202 Clinical Study ASCO Oral Presentation to Highlight 65% Objective Response Rate (ORR) and 30% Complete Response Rate Nearly All Responses Remain Ongoing at a Median Follow-up of 21.7 Months in the Oral Presentation Data in Published Abstract and Upcoming Oral Presentation Strongly...Read more


Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

May 23
Last Trade: 35.23 0.00 0.00

NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 clinical trial with vepdegestrant, a novel investigational oral PROteolysis Targeting Chimera (PROTAC®) ER degrader, in combination with Pfizer’s atirmociclib (PF-07220060), an investigational CDK4 inhibitor, were accepted for presentation at...Read more


Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

May 23
Last Trade: 34.05 -0.19 -0.55

Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024 KT-253 Phase 1 study ongoing with additional data expected in the second half of 2024 WATERTOWN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...Read more


Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

May 23
Last Trade: 24.13 1.48 6.53

Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer (NSCLC) with oncogenic mutations Longer term follow-up for patients treated with CLN-619 monotherapy demonstrates durable clinical benefit across multiple tumor types CLN-619 continues to demonstrate a favorable...Read more


Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product

May 23
Last Trade: 4.63 -0.50 -9.75

Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Top line results imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea 18 million people in U.S. are living with a cancer diagnosis and more than 2 million people in U.S. are expected to be diagnosed...Read more


Tyra Biosciences to Present at Upcoming Investor Conferences

May 23
Last Trade: 17.32 0.32 1.88

CARLSBAD, Calif., May 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: TD Cowen's 5th Annual Oncology Innovation Summit: Insights for ASCO &...Read more


Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting

May 23
Last Trade: 23.03 -0.45 -1.92

Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates® demonstrate differentiation compared to antibody drug conjugates Trial-in-progress poster outlines registrational Phase 2/3 Duravelo-2 trial of BT8009, a Nectin-4 targeted Bicycle Toxin Conjugate, in patients with locally advanced or metastatic urothelial cancer Zelenectide pevedotin selected as International Nonproprietary Name for BT8009 FDA Fast Track...Read more


Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing

May 23
Last Trade: 23.03 -0.45 -1.92

Financing includes participation from new and existing investors Strengthens balance sheet, with pro forma cash position of approximately $1.0 billion, extending expected financial runway into the second half of 2027 Supports ongoing advancement of pipeline with multiple clinical-stage precision-guided therapeutics CAMBRIDGE, England & BOSTON / May 23, 2024 / Business Wire / Bicycle Therapeutics plc (NASDAQ: BCYC), a...Read more


CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update

May 23
Last Trade: 3.69 -0.28 -7.05

Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year end U.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1) vaccine currently in Phase 1 development; candidate jointly developed with GSK Settlement with Acuitas Therapeutics includes acknowledgment of CureVac's ownership of certain patent claims and Acuitas's licenses to selected...Read more


Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting

May 23
Last Trade: 11.27 -0.01 -0.09

Administration of azenosertib combined with gemcitabine was well tolerated and resulted in clinically meaningful increase in event-free survival compared to historical comparators Results support further evaluation of azenosertib combined with gemcitabine in relapsed or refractory osteosarcoma through an investigator-initiated Phase 2 trial NEW YORK and SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc....Read more


PureTech Health to Present at the Jefferies Global Healthcare Conference

May 23
Last Trade: 29.25 0.00 0.00

BOSTON / May 23, 2024 / Business Wire / PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Bharatt Chowrira, Ph.D., J.D., Chief Executive Officer, and Eric Elenko, Ph.D., Co-founder and President, will participate in a fireside chat at the Jefferies Global Healthcare Conference on...Read more


Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting

May 23
Last Trade: 8.22 0.73 9.75

Bezuclastinib + sunitinib combination therapy reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST patients with one prior treatment Encouraging long-term safety and tolerability with combination bezuclastinib and sunitinib therapy in Part 1 PEAK Phase 3 guidance accelerated with enrollment completion now expected in 3Q 2024 Company announces new advanced GIST clinical trial sponsored...Read more


Calliditas Therapeutics Q1 report, January - March 2024

May 23
Last Trade: 22.42 -0.33 -1.45

STOCKHOLM, May 23, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALTX) (STOCKHOLM: CALTX): Target market expansion following full approval in the US JANUARY - MARCH 2024 (COMPARED TO JANUARY - MARCH 2023) Net sales amounted to SEK 295.5 million, of which TARPEYO® net sales amounted to SEK 278.3 million, for the three months ended March 31, 2024. For the three months ended March 31, 2023, net sales amounted to SEK...Read more


Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

May 23
Last Trade: 9.02 0.00 0.00

BOSTON / May 23, 2024 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024. Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité...Read more


Corbus Pharmaceuticals: Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

May 23
Last Trade: 45.02 3.64 8.80

NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701),...Read more


Adlai Nortye to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

May 23
Last Trade: 10.50 -1.53 -12.72

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally...Read more


Tourmaline Bio to Present at the Jefferies Global Healthcare Conference

May 23
Last Trade: 13.45 -0.21 -1.54

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, is expected to participate in the following investor conference: Jefferies Global Healthcare Conference, New...Read more


Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

May 23
Last Trade: 1.36 0.02 1.49

GERMANTOWN, Md., May 23, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host a webcast on June 3, 2024 at 6:00 PM CT/7:00 PM ET following the late-breaking oral presentation of results from the pivotal study of PRGN-2012 for the treatment of recurrent...Read more


Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23
Last Trade: 5.22 -0.44 -7.77

WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced multiple presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 31-June 4, 2024. The Company has two abstracts selected for oral presentation, including an...Read more


Agenus: Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting

May 23
Last Trade: 13.62 1.27 10.28

New analysis highlights BOT/BAL activity across challenging metastatic disease sites LEXINGTON, Mass. / May 23, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced a novel analysis from the Phase 1b trial of botensilimab in combination with balstilimab (BOT/BAL) in relapsed/refractory microsatellite stable colorectal cancer (r/r MSS...Read more


Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences

May 23
Last Trade: 4.57 0.01 0.22

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the Company will present recently announced topline data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1...Read more


atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

May 23
Last Trade: 1.61 -0.02 -1.23

NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements. Scott Braunstein, M.D., is...Read more


Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

May 23
Last Trade: 7.80 -2.89 -27.03

Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease despite immune checkpoint inhibitor therapy compared to published results of median overall survival of 11.6 months observed with standard of care docetaxel-based chemotherapy in a similar patient population CAN-2409 treatment resulted in activation of the systemic immune response after...Read more


Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

May 23
Last Trade: 1.10 0.01 0.92

CAMBRIDGE, Mass., May 23, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5 at 9:00 a.m. ET. The Jefferies Global Healthcare Conference will take place in New York, NY on June 4-6,...Read more


Coherus BioSciences Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

May 23
Last Trade: 1.91 -0.10 -4.98

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA on Wednesday, May 29, 2024 at 12:00 p.m. Eastern Daylight Time / 9:00 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events...Read more


Coherus BioSciences Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23
Last Trade: 1.91 -0.10 -4.98

CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained over the dosing interval, establishing proof of mechanism Preclinical data and preliminary clinical results support further evaluation of CHS-114 in combination with the anti-programmed...Read more


G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting

May 23
Last Trade: 4.09 -0.13 -3.08

RESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that mature Phase 2 results describing the positive impact of trilaciclib administered in combination with the TROP2 antibody-drug conjugate (ADC) sacituzumab govitecan (SG) on overall survival (OS) and tolerability compared to SG alone based on historical data from the ASCENT trial will...Read more


Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

May 23
Last Trade: 4.88 -0.28 -5.43

Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers  Preliminary data on WTX-124 administered in combination with pembrolizumab show similar tolerability to WTX-124 monotherapy  Additional details and data post abstract cut-off date to be presented at ASCO  Company to host...Read more


Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at American Society of Clinical Oncology Annual Meeting

May 23
Last Trade: 1.47 -0.03 -1.67

CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic or locally advanced malignancies who had progressed on approved PD-1 or PD-L1 inhibitors. Five clinical responses were observed, all in patients who previously received checkpoint inhibitors. A durable partial response (PR) in a patient...Read more


Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

May 23
Last Trade: 4.00 0.01 0.25

LOS ANGELES / May 23, 2024 / Business Wire / Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of abstracts on alisertib to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting will be held at McCormick Place in Chicago and online from May 31-June 4. Full abstracts of the following posters are available online at...Read more


Rigel Pharmaceuticals Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

May 23
Last Trade: 0.91 0.0044 0.49

Oral presentation of final five-year results from the registrational Phase 2 trial in R/R mIDH1 AML patients reinforces REZLIDHIA® (olutasidenib) efficacy in heavily pretreated patients, including those receiving prior venetoclax Other key posters further support the efficacy of REZLIDHIA® (olutasidenib) in elderly, transplant-eligible, and post-MPN patients with AML SOUTH SAN FRANCISCO, Calif., May 23, 2024 /PRNewswire/ -- Rigel...Read more


I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

May 23
Last Trade: 1.75 0.00 0.00

Encouraging objective responses were observed in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR), mainly in patients previously treated with checkpoint inhibitors Phase 1 dose-escalation data demonstrated that ragistomig monotherapy can be safely administered through the highest planned doses Data will be presented at the 2024 Annual Meeting of the American Society of Clinical...Read more


FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology...

May 23
Last Trade: 1.30 0.02 1.56

FG-3246 and enzalutamide combination therapy led to a median radiographic progression free survival (rPFS) of 10.2 months in biomarker unselected patients FG-3246 demonstrated an acceptable safety profile; adverse events consistent with those observed in other antibody drug conjugate therapies with a MMAE payload Recommended Phase 2 dose of FG-3246 was established at 2.1 mg/kg every 3 weeks in combination with enzalutamide given at...Read more


Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference

May 23
Last Trade: 4.08 -0.02 -0.49

SOUTH SAN FRANCISCO, Calif. / May 23, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters highlighting fasedienol, its investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder...Read more


Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

May 23
Last Trade: 3.90 0.04 1.04

Eight of nine patients responding to the treatment, plus the encouraging safety data observed in the RESOLVE Phase 1b/2a trial of EP-104GI, provided the catalyst for the trial expansion Early low-dose cohorts showing meaningful improvement in patient symptoms and biological evidence of disease Trial expansion allows more patients to be treated at higher doses and followed for up to 52 weeks, up from 24 weeks VICTORIA, BC, May 23,...Read more


Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​

May 23
Last Trade: 4.12 -8.06 -66.17

83% (5/6) of patients achieved a confirmed partial response in cohort 1, the most mature dose level; one dose-limiting toxicity was observed, however, the dose level was subsequently cleared after additional patients were enrolled Follow up of patients in the additional dose and schedule cohorts is ongoing to determine the recommended Phase 2 dose​ for study expansion Poster presentation on Saturday, June 1, 2024 at the ASCO Annual...Read more


Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

May 23
Last Trade: 8.41 -0.44 -4.97

ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levels ELI-002 7P generated an mKRAS-specific T cell response in 100% of patients including responses targeting all mKRAS mutations enrolled (G12D, V, R and G13D) mKRAS-specific T cells were polyfunctional with 66.7% (4/6) of evaluable patients having both CD8+ and CD4+ responses at the...Read more


IO Biotech to Present at Jefferies Global Healthcare Conference

May 23
Last Trade: 1.27 -0.05 -3.79

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company’s CFO, will be participating in one-on-one investor meetings at the Jefferies Global...Read more


BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23
Last Trade: 1.71 -0.39 -18.57

Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug High doses of evalstotug as either a monotherapy or in combination with PD1 are associated with manageable safety with relatively low incidence and severity of immune-mediated AEs allowing patients to continue treatment for extended intervals    On track...Read more


HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting

May 23
Last Trade: 0.80 -0.24 -23.08

HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4 Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile and promising clinical activity In a subset of patients with PD-L1 combined positive score (CPS) of 20 or higher, data showed confirmed objective response rate (ORR) of 53%, complete response (CR) rate of 18%, and disease control rate...Read more


Genelux Announces Proposed Public Offering of Common Stock and Warrants

May 23
Last Trade: 2.62 -1.98 -43.04

WESTLAKE VILLAGE, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants. All shares of common stock and accompanying warrants are being offered by Genelux. In addition, Genelux expects to grant the underwriters a 30-day option to purchase up to...Read more


Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024

May 23
Last Trade: 4.19 -0.52 -11.04

In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the combination of AFM24 and atezolizumab led to a disease control rate of 73.3% (11/15), including 4 objective responses (1 complete and 3 partial responses) As of the March 18, 2024 data cut-off, the median progression free survival was 5.9 months and 3 of 4 responses were...Read more


Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting

May 23
Last Trade: 3.59 0.00 0.00

ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3 and was generally well-tolerated at all doses tested Less frequent dosing regimen, a shift from five daily infusions to two infusions per three-week cycle, is being evaluated as both a single agent and in combination with pembrolizumab in...Read more


Lexaria Bioscience Awards Contract For Third GLP-1 Human Pilot Study

May 23
Last Trade: 3.12 0.24 8.33

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format KELOWNA, BC / ACCESSWIRE / May 23, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has hired a contract research organization ("CRO") to perform the Company's human pilot study #3, (the "Study") which will evaluate a dual action GLP-1...Read more


Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23
Last Trade: 0.76 -0.21 -22.09

KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed  KB-0742 continues to show dose linear pharmacokinetics up to 80mg three-days-on, four-days-off dose, including increased target engagement at the 80mg vs. 60mg doses  The escalation cohort at 80mg four-days-on, three-days-off is currently enrolling, and the expansion cohort at this dose is expected to begin...Read more


Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 23
Last Trade: 1.84 0.02 1.10

nab-Sirolimus demonstrated significantly greater intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity compared to IV and oral mTOR inhibitors in a xenograft model Data support further clinical exploration of nab-sirolimus as a single agent or in combination LOS ANGELES, May 23, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company...Read more


IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

May 23
Last Trade: 1.01 -0.03 -2.88

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming presentation of updated results from its fully enrolled Phase 1 study of INB-200 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 31st - June 4th in Chicago, Illinois. INB-200 is evaluating autologous Drug...Read more


NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23
Last Trade: 1.42 -0.44 -23.66

SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better overall synergy in future combination regimens with immune checkpoint inhibitors. In this Phase 1 trial, the best objective response of stable disease was demonstrated in 100% of patients that completed 8 treatment cycles of SNK02. SNK02 was well...Read more


Evaxion Biotech to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

May 23
Last Trade: 4.04 0.16 4.12

EVX-01 induced positive clinically relevant immune responses in all assessed patients Booster immunizations tended to increase the immune response The observed immune responses were mediated by both CD4+ and CD8+ T-cells COPENHAGEN, Denmark, May 23, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines,...Read more


Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

May 23
Last Trade: 0.79 -0.66 -45.52

Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity  Pharmacokinetic and safety profile validate conditionally active approach  Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET  BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...Read more


Kane Biotech Announces First Quarter 2024 Financial Results

May 23
Last Trade: 0.13 -0.02 -13.33

WINNIPEG, Manitoba, May 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its first quarter 2024 financial results. The Company previously announced on April 11, 2024 that it had reached an agreement in principle for the sale of its entire interest in STEM Animal Health Inc. (“STEM”) to a third party multi-national pharmaceutical company on a cash-free debt-free...Read more


TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing

May 23
Last Trade: 2.21 0.17 8.33

The Leidos team’s Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company’s Proprietary Thin Film Freezing Technology MCM Candidates Demonstrated Chemical and Biological (CB) Neutralizing Activity in Well-Validated In Vitro and Ex Vivo Models FORT WORTH, Texas, May 23, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on...Read more


Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement

May 23
Last Trade: 0.08 -0.005 -5.88

All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the undertaking of a non-brokered Private Placement (the “Offering”) for gross proceeds of up to $1.5...Read more


Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

May 23
Last Trade: 0.30 -0.03 -10.06

ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to lead clinical candidate VCN-01 in combination with gemcitabine and nab-paclitaxel to improve...Read more


Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

May 23
Last Trade: 0.77 -0.0028 -0.36

Phio to present a clinical study progress update on their lead clinical candidate, PH-762 Marlborough, Massachusetts--(Newsfile Corp. - May 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting data about its lead product candidate,...Read more


Bio-Path to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting

May 23
Last Trade: 2.03 0.02 1.00

HOUSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 - June 4, 2024 in Chicago, IL. Maro Ohanian, D.O.,...Read more


Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting

May 22
Last Trade: 166.61 2.60 1.59

Moderna to host an investor event via webcast on Monday, June 3 at 6:15 PM CDT CAMBRIDGE, MA / ACCESSWIRE / May 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 - June 4 in Chicago, IL. mRNA-4157...Read more


Bio-Techne Highlights Recently Announced Top-Line Biomarker Data From Partner, Regulus Therapeutics, Using The Company's Proprietary Technology

May 22
Last Trade: 80.79 0.38 0.47

MINNEAPOLIS, May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced continued technical and clinical collaboration following release of Regulus' positive topline results from the second cohort of patients in its Phase 1b MAD (multiple ascending dose) study of RGLS8429...Read more


Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

May 22
Last Trade: 26.62 -0.23 -0.86

Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s...Read more


Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism

May 22
Last Trade: 106.06 2.12 2.04

DUBLIN, May 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a strategic collaboration with Life Science Cares to drive social impact through employee volunteerism in the United States. This partnership reinforces Jazz's commitment to supporting the communities in which employees work and live. Life Science Cares is a collective effort to activate the financial and human capital of the life sciences...Read more


Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

May 22
Last Trade: 48.30 -0.68 -1.39

SOUTH SAN FRANCISCO, Calif. and NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Royalty Pharma plc (Nasdaq: RPRX) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed...Read more


Cytokinetics Announces Proposed Public Offering of Common Stock

May 22
Last Trade: 48.30 -0.68 -1.39

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $500 million of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Cytokinetics expects to grant the underwriters a...Read more


Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

May 22
Last Trade: 47.47 -1.16 -2.39

SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that the late-breaking abstracts accepted for presentation at the Endocrine Society’s annual meeting (ENDO 2024) were released earlier than the previously...Read more


Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024

May 22
Last Trade: 48.23 0.24 0.50

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference at 9:40 a.m. ET on Wednesday, May 29, 2024. A webcast of the presentation will be available on the...Read more


Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

May 22
Last Trade: 36.76 -0.61 -1.63

BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the National Institute for Health and Care Excellence (NICE) has issued guidance that recommends IMCIVREE® (setmelanotide) as an option for treating obesity and the control of...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Today's Biotech Gainers

 
CompanyChangeLast Trade
Merus 15.92 36.12 $59.99
Third Harmonic Bio 6.79 94.31 $13.99
Vertex Pharmaceuticals 6.15 1.36 $456.95
argenx 6.05 1.68 $367.07
Regeneron Pharmaceuticals 4.45 0.45 $985.02
Corbus Pharmaceuticals 3.64 8.80 $45.02
Morphic Therapeutic 3.04 10.95 $30.80
Moderna 2.60 1.59 $166.61
Janux Therapeutics 2.35 5.46 $45.37
Jazz Pharmaceuticals 2.12 2.04 $106.06
SIGA Technologies 2.02 37.13 $7.46
Apogee Therapeutics 1.99 4.32 $48.03
Avalo Therapeutics 1.95 17.49 $13.10
Legend Biotech 1.91 4.84 $41.41
Immatics 1.88 19.14 $11.70
Surmodics

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...

CLICK TO LEARN MORE
List of Biotech Stocks

Biotech Stocks

Featured Stock

Surmodics

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB